Clinical Trials
18 trialsNCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT05260203 2024-11-06
MargheRITA
Advice Pharma Group srl
Phase NA Completed
NCT03755154 2024-10-16
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT05032339 2023-10-30
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyricâ„¢ Flow Cytometer
Becton, Dickinson and Company
Completed
NCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00446342 2017-04-11
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Sunesis Pharmaceuticals
Phase 1 Completed
NCT01344876 2015-06-08
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Otsuka Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT00070616 2014-10-24
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Swedish Orphan Biovitrum
Phase 1 Completed
NCT01435720 2014-09-11
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.
Phase 1/2 Unknown
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00825487 2011-10-19
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00460460 2011-01-25
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
AstraZeneca
Phase 1 Terminated
NCT00195533 2009-11-16
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Completed